

WÓJCIK, Aleksandra, NIEDOBYLSKI, Sylwiusz, WRONA, Joanna, MADYCKA, Daria, WNUCZEK, Kinga, STAROWNIK, Jakub and MICHTA, Kacper. Acne vulgaris in adolescents – the review. *Quality in Sport*. 2024;27:55267. eISSN 2450-3118.
<https://dx.doi.org/10.12775/QS.2024.27.55267>
<https://apcz.umk.pl/QS/article/view/55267>

The journal has been 20 points in the Ministry of Higher Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Higher Education and Science of 05.01.2024. No. 32553.

Has a Journal's Unique Identifier: 201398. Scientific disciplines assigned: Economics and finance (Field of social sciences); Management and Quality Sciences (Field of social sciences).

Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 r. Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398.

Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).

© The Authors 2024;

This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (<http://creativecommons.org/licenses/by-nc-sa/4.0/>) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 18.09.2024. Revised: 18.10.2024. Accepted: 21.10.2024. Published: 22.10.2024.

Acne vulgaris in adolescents – the review

Aleksandra Wójcik¹

<https://orcid.org/0000-0003-1669-7466>;

awojcik115@gmail.com

Sylwiusz Niedobylski²

<https://orcid.org/0000-0001-7266-623X>;

sniedobylski@gmail.com

Joanna Wrona¹

<https://orcid.org/0009-0004-9267-1529>;

joanna.alicja.wrona@gmail.com

Daria Madycka¹

<https://orcid.org/0000-0001-8682-1229>;

dariaem16@gmail.com

Kinga Wnuczek¹

<https://orcid.org/0009-0001-6687-075X>;

wnuczek.kinga@gmail.com

Jakub Starownik³

<https://orcid.org/0009-0008-2711-2578>;

jakub.starownik2@gmail.com

Kacper Michta²

<https://orcid.org/0000-0003-3303-4859>;

kacper.michtaa@gmail.com

¹Medical University of Lublin, Poland

² The Independent Public Hospital No. 4 in Lublin, Poland

³ Military Institute of Medicine – National Research Institute, Warsaw, Poland

Abstract

Acne vulgaris is one of the most common chronic inflammatory skin disorders that affects almost 90% of the adolescents worldwide. Due to its effect on one's appearance, it causes not only physical but also psychological consequences. The cause of acne involves increased sebum production, hyperkeratinisation of the follicle, bacterial colonization and inflammation, which result in formation of comedones, papules, pustules and nodules. Diet, Body Mass Index, hyperhidrosis and stress can be triggering factors. The pharmacological treatment of acne involves substances administered topically as well as orally. First line of treatment of mild-to-moderate acne involves topical benzoyl peroxide, retinoids, chemical peels, antibiotics and combinations of those agents. The treatment of moderate-to-severe or inflammatory acne consists of oral antibiotics, isotretinoin, oral contraceptives and spironolactone. New therapies are being investigated and show a great potential, however further research should be pursued in order to achieve long-lasting results of the treatment.

Keywords: adolescent acne, acne vulgaris, skin disorder

Introduction

Acne vulgaris (hereafter acne) is one of the most common chronic inflammatory skin disorders, affecting almost 90% of the adolescents worldwide¹. It is caused by increased sebum production, follicle hyperkeratinisation, bacterial colonization and inflammation. Clinical presentation involves open or closed comedones, papules, pustules and nodules that are mostly localized on the face and neck, but can also develop on the chest, back and buttocks². Although there is no mortality associated with acne, the condition due to its visible nature may negatively influence psychological wellbeing³. That is why it is essential to understand the nature of the disease and find a suitable and effective treatment for everyone.

Epidemiology

Acne vulgaris is commonly observed in adolescents and young adults. Adolescent acne begins at puberty, when the levels of sex hormones start to increase. The occurrence of acne among girls increases from 61% at age 12 years up to 83% at age 16 years, whereas in boys it increases from 40% up to 95%, respectively². In contrast to adulthood where there is a female predominance, during adolescence this disorder is more common in males, especially with more severe forms of acne⁴. Western Europe, North America and Latin America are reported to have the highest prevalence of acne. Moreover, this disorder is considered to be the 8th most common disease in the world, as it affects people from adolescence up to the early thirties⁵.

According to Zaenglein et al. acne affects approximately 50 million people in the United States (US). Despite appearing in most age groups, acne occurs in 85% of teenagers in the US³. Although there is no mortality connected to this disorder, it is associated with significant physical and psychological morbidity. The remaining permanent scars and pigmentation combined with negative effect on psychological wellbeing, may lead to poor self-esteem, anxiety and finally depression⁶.

Pathophysiology and clinical presentation

Although the current understanding of acne pathogenesis is constantly evolving, it involves few key pathogenic factors such as excess sebum production, hyperkeratinisation in the pilosebaceous follicle, colonisation by *Cutibacterium acnes* (*C. acnes*) and inflammation caused by complex immune reactions⁶. What is more, it is suggested that high levels of androgens, diet and genetic factors may all be involved in the acne development³.

The clinical presentation of acne starts with a primary lesion, which is called a microcomedo and is caused by the follicular hyperkeratosis that obstructs the flow of sebum onto the surface of the skin². It is a precursor for all clinical manifestations of acne. Microcomedos evolve into other acne lesions such as comedones known as whiteheads, open comedones known as blackheads and inflammatory pustules, papules and nodules⁷.

The microcomedo is a suitable environment for *C. acnes* proliferation, population of which increases significantly during puberty, which causes higher secretion of pro-inflammatory mediators that cause an inflammatory response⁸. Cytotoxic free fatty acids are released into the skin due to follicular breakdown and contribute to the inflammatory reaction. Furthermore, the production of pro-inflammatory cytokines (IL-1, IL-8, IL-12) and defensins is initiated by recruited inflammatory cells and leads to the formation of inflammatory papules, pustules, and nodules².

The role of genetics in acne development is substantial, as the risk of developing acne in individuals with affected first-degree family member is estimated to be as high as 3 times greater than in individuals without a family history of acne⁷.

Acne vulgaris occurs most commonly in areas of the body with abundant number of sebaceous glands, such as face (in 92% of cases), back (61%) and chest (45%)⁶. Neck and proximal upper extremities can also be affected by inflammatory and non-inflammatory lesions².

There are several clinical variants of acne. Acne conglobata, which is a severe and highly inflammatory type of acne occurs mostly in young males. It is characterized by the presence of grouped comedones, painful lesions and interconnecting deep-seated foul-smelling abscesses, located mainly on the face, chest, back, thighs and the buttocks. It may lead to significant scarring and disfigurement⁹. Another variant of acne is acne fulminans, a rare form that is characterized by sudden appearance of ulcerative nodules and haemorrhaging pustules paired with high fever, weight loss, bone lesions and elevated liver enzymes^{10,11}. Neonatal acne, infantile acne, mid-childhood and preadolescent acne are prepubertal conditions and they do not occur as often as adolescent acne^{2,12}.

Triggering factors

The evidence connecting diet and acne is increasing. Scientists discovered a significant relationship between acne severity and dietary factors. High consumption of milk, cheese, yoghurt, chocolate and low consumption of vegetables, fruits and fish is closely associated with adolescent acne morbidity^{13,14}. Although there are contradictory results regarding the relationship between Body Mass Index (BMI) and acne, most studies showed that individuals with higher BMI have elevated risk of the disease¹⁵. Additionally, the obesity in female adolescents with Polycystic Ovary Syndrome leads to insulin resistance and hyperinsulinemia, which results in hyperandrogenism and high levels of free testosterone, finally resulting in acne^{4,14,16}.

Another factor taken into consideration while assessing factors that trigger acne is hyperhidrosis. Although there are not many studies that confirm a clear relationship between excessive sweating and acne, a review conducted by Kutlu et al. reports that acne is indeed aggravated by sweating and exposure to hot weather⁴.

Furthermore, individuals that are exposed to emotional stress may also be more prone to acne. Stress stimulates androgen hormones production. It also may alter the adrenal-pituitary axis, resulting in higher levels of cortisol. Moreover, the risk of inflammation and scarring is higher by stress-induces skin-picking and excoriations⁴.

Treatment

When it comes to treatment of acne, a holistic approach is essential. The goals of therapy are to minimize scarring, provide the patient with the best appearance possible and manage psychological consequences. The first line of treatment for mild-to-moderate acne are topical agents, which have a favourable safety profile. For moderate-to-severe acne and acne that does not respond to topical agents, systemic therapies are usually prescribed².

The most common topical acne therapies include benzoyl peroxide, antibiotics, retinoids, combination of antibiotics with benzoyl peroxide, retinoid with benzoyl peroxide, retinoid with antibiotic, salicylic and glycolic acid³.

Benzoyl peroxide is an antibacterial agent active against *C. acnes*. It also has anti-inflammatory properties, as well as comedolytic activity. The treatment of acne can be carried out with benzoyl peroxide alone or in combination with salicylic acid, retinoid, zinc or antibiotics such as clindamycin or erythromycin¹⁷.

The retinoids are vitamin A derivatives, which inhibit the formation of new lesions, (such as comedones as well as inflammatory and non-inflammatory lesions) by decreasing cellular proliferation and differentiation¹⁸. Retinoids also have anti-inflammatory properties¹⁹. What is more, they reduce and prevent the appearance of dyspigmentation and atrophic scars²⁰. There are three retinoids viable for topical treatment: tretinoin, adapalene and tazarotene. Although those agents can enhance any topical acne regimen, their use may be limited by the side effects such as dryness, peeling and irritation, which often results in the discontinuation of the treatment²¹. Furthermore, topical retinoid agents have been associated with an increased risk of photosensitivity, which is why daily sunscreen application is required. Although the therapy with retinoids in children <12 years of age is limited, a few changes have been recently introduced.

The combination of 2.5% benzoyl peroxide with 1% adapalene gel has been approved in patients ≥ 9 years old as well as 0.05% micronized tretinoin gel for patients ≥ 10 years of age³. Chemical peeling is a process used in treatment of acne that causes controlled chemical injury to the skin and removal of superficial lesions resulting in regeneration of new tissues²². Glycolic acid (GA) is a water-soluble alpha-hydroxy acid and is used in treatment as a chemical peel. High concentrations of GA (20-70%) have proved to be effective in acne treatment, however such concentrations should only be used in the hospital or dermatology clinic²³. GA in low concentrations ($<10\%$) may be beneficial to the skin and can be safely used at home²⁴. Another chemical peel used in acne treatment is salicylic acid (SA), a Beta-hydroxyl acid with keratolytic and anti-inflammatory properties. Although SA is not toxic when applied with caution and can be used for all stages of active acne, it can be toxic when applied to large area. Such toxicity is called Salicylism and is usually associated with systemic absorption and high concentration of the acid. Both GA (30-70%) and SA (30%) are considered to be effective in treatment of acne²⁵.

Overall, when it comes to topical treatment of acne, topical treatment combinations are significantly more effective than topical agents used as a monotherapy²⁶.

The first line of systemic treatment for moderate-to-severe or inflammatory acne are oral antibiotics. As monotherapy of oral antibiotics in acne treatment is not recommended, they should be combined with topical retinoids and/or benzoyl peroxide. Although the most common antibiotics prescribed for acne treatment are tetracyclines, which penetrate the pilosebaceous unit, macrolides are also prescribed to patients that cannot use tetracyclines²⁷. What is more, in order to avoid development of antibiotic resistance, oral antibiotics should constitute a bridge to other oral therapies and should not be used longer than 6 months^{20,28}.

Severe recalcitrant cases of acne vulgaris may be treated with isotretinoin, a retinoid that reduces the size of sebaceous glands, regulates cell proliferation, lowers sebum excretion and decreases keratinization. It also possesses anti-inflammatory and immunomodulatory properties that can be used for various skin diseases, not only acne²⁹. Moreover, oral isotretinoin could be an effective treatment option for reducing the size of scars and their severity and at the same time improving the elasticity of the skin³⁰. Although it is highly effective, isotretinoin has some adverse effects. Many patients may suffer from xerostomia (dry mouth), xerosis (dry skin), dry nose, ophthalmic changes, laboratory abnormalities as well as sun sensitivity and 90% of individuals will likely develop dry lips and cheilitis³¹. Isotretinoin is also highly teratogenic, which is why women of childbearing age should not be given oral isotretinoin until pregnancy is excluded and an effective contraceptive agent is administered³².

For women in post-menarche with moderate-to-severe acne typically over the age of 15 years the use of oral contraceptives should be considered. Oestrogens present the ability to suppress the stimulatory effects of androgens allowing to decrease the size and activity of sebaceous glands. However, oral contraceptives have some adverse effects such as headaches, moodiness, nausea, bloating, breast tenderness, hypertension and, most severe, thromboembolisms^{2,33}.

Spironolactone is a potassium-sparing diuretic that has an anti-androgenic effect³⁴. It is used in women that have elevated levels of androgens and are refractory to topical acne agents².

Since spironolactone showed similar efficacy compared to oral antibiotics, it is recommended as first choice while establishing the course of the therapy, as the risk of antibiotic resistance is growing^{35,36}. Breast enlargement and tenderness, menstrual irregularities, headache, nausea, diarrhoea, vomiting, orthostatic hypotension and hyperkalaemia are possible side effects².

Other than the aforementioned, new forms of acne treatment are being developed. Anti-acne microneedle patches have been investigated by Tai et al. and showed to be a safe and effective treatment in acne and post-inflammatory hyperpigmentation, without adverse skin reactions³⁷. What is more, inflammatory and non-inflammatory acne in adolescent can be safely controlled with the intralesional platelet-rich plasma injections and 1064 nm long-pulsed Nd:YAG laser³⁸.

Conclusions

Despite significant advances in the treatment of acne vulgaris, it remains a great inconvenience for not only adolescents, but also other age groups. Although most acne therapies are effective, the results are often not long-lasting, which may be frustrating for patients that struggle with long-term treatment. New approaches in therapy are promising, however, there should be more research dedicated to the area of the post-treatment results.

In conclusion, acne vulgaris is a condition that affects not only physical, but also psychological aspects of patients' life, thus the approach to treating the disease should be holistic.

Disclosure

Author's Contribution

Conceptualization - Aleksandra Wójcik; Methodology - Aleksandra Wójcik, Sylwiusz Niedobyłski, Joanna Wrona, Daria Madycka, Kinga Wnuczek, Jakub Starownik, Kacper Michta; Software - Aleksandra Wójcik, Sylwiusz Niedobyłski, Joanna Wrona, Daria Madycka, Kinga Wnuczek, Jakub Starownik, Kacper Michta; Check - Aleksandra Wójcik, Sylwiusz Niedobyłski, Joanna Wrona, Daria Madycka, Kinga Wnuczek, Jakub Starownik, Kacper Michta; Formal analysis - Aleksandra Wójcik, Sylwiusz Niedobyłski, Joanna Wrona, Daria Madycka, Kinga Wnuczek, Jakub Starownik, Kacper Michta; Investigation - Aleksandra Wójcik, Sylwiusz Niedobyłski, Joanna Wrona, Daria Madycka, Kinga Wnuczek, Jakub Starownik, Kacper Michta; Resources - Aleksandra Wójcik, Sylwiusz Niedobyłski, Joanna Wrona, Daria Madycka, Kinga Wnuczek, Jakub Starownik, Kacper Michta; Data curation - Aleksandra Wójcik, Sylwiusz Niedobyłski, Joanna Wrona, Daria Madycka, Kinga Wnuczek, Jakub Starownik, Kacper Michta; Writing (rough preparation) - Aleksandra Wójcik, Sylwiusz Niedobyłski, Joanna Wrona, Daria Madycka, Kinga Wnuczek, Jakub Starownik, Kacper Michta; Writing (review and editing) - Aleksandra Wójcik, Sylwiusz Niedobyłski, Joanna Wrona, Daria Madycka, Kinga Wnuczek, Jakub Starownik, Kacper Michta; Visualization - Aleksandra Wójcik, Sylwiusz Niedobyłski, Joanna Wrona, Daria Madycka, Kinga Wnuczek, Jakub Starownik, Kacper Michta; Supervision - Aleksandra Wójcik; Project administration Aleksandra Wójcik;

All authors have read and agreed with the published version of the manuscript.

Funding Statement

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflict of Interest Statement

The authors declare no conflict of interest.

References

1. Diogo MLG, Campos TM, Fonseca ESR, et al. Effect of Blue Light on Acne Vulgaris: A Systematic Review. *Sensors*. 2021;21(20):6943. doi:10.3390/s21206943
2. Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Dermatology: how to manage acne vulgaris. *Drugs Context*. 2021;10:2021-8-6. doi:10.7573/dic.2021-8-6
3. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. *J Am Acad Dermatol*. 2016;74(5):945-973.e33. doi:10.1016/j.jaad.2015.12.037
4. Kutlu Ö, Karadağ AS, Wollina U. Adult acne versus adolescent acne: a narrative review with a focus on epidemiology to treatment. *An Bras Dermatol*. 2023;98(1):75-83. doi:10.1016/j.abd.2022.01.006
5. Łożyńska K, Głąbska D. Association between Nutritional Behaviours and Acne-Related Quality of Life in a Population of Polish Male Adolescents. *Nutrients*. 2022;14(13):2677. doi:10.3390/nu14132677
6. Layton AM, Ravenscroft J. Adolescent acne vulgaris: current and emerging treatments. *Lancet Child Adolesc Health*. 2023;7(2):136-144. doi:10.1016/S2352-4642(22)00314-5
7. Sutaria AH, Masood S, Saleh HM, Schlessinger J. Acne Vulgaris. In: *StatPearls*. StatPearls Publishing; 2024. Accessed August 6, 2024. <http://www.ncbi.nlm.nih.gov/books/NBK459173/>
8. Imahiyerobo-Ip JI, Dinulos JG. Changing the topography of acne with topical medications. *Curr Opin Pediatr*. 2011;23(1):121. doi:10.1097/MOP.0b013e3283425457
9. Hafsi W, Arnold DL, Kassardjian M. Acne Conglobata. In: *StatPearls*. StatPearls Publishing; 2024. Accessed August 9, 2024. <http://www.ncbi.nlm.nih.gov/books/NBK459219/>
10. Dall'oglio F, Puglisi DF, Nasca MR, Micali G. Acne fulminans. *G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr*. 2020;155(6):711-718. doi:10.23736/S0392-0488.20.06711-5
11. Gutiérrez-Meré R, Tajés I, Diéguez P, Soto-García D, Martínez-Fernández S, Batalla A. Acne Fulminans: A Narrative Review. *Actas Dermosifiliogr*. 2023;114(9):763-771. doi:10.1016/j.ad.2023.05.018
12. Poole CN, McNair V. Infantile Acne. In: *StatPearls*. StatPearls Publishing; 2024. Accessed August 9, 2024. <http://www.ncbi.nlm.nih.gov/books/NBK541124/>
13. Karadağ AS, Balta I, Saricaoglu H, et al. The effect of personal, familial, and environmental characteristics on acne vulgaris: A prospective, multicenter, case controlled study. *G Ital Dermatol Venereol*. 2019;154(2):177-185. doi:10.23736/S0392-0488.17.05532-8
14. Melnik BC. Linking diet to acne metabolomics, inflammation, and comedogenesis: an update. *Clin Cosmet Investig Dermatol*. 2015;8:371-388. doi:10.2147/CCID.S69135

15. Di Landro A, Cazzaniga S, Parazzini F, et al. Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults. *J Am Acad Dermatol*. 2012;67(6):1129-1135. doi:10.1016/j.jaad.2012.02.018
16. Wójcik A, Wojtas J, Margas M, Warchoń K, Stępnia K. How do new therapeutic strategies for PCOS management influence the health of the affected individuals? The narrative review. *J Educ Health Sport*. 2022;12(10):294-300. doi:10.12775/JEHS.2022.12.10.035
17. Yang Z, Zhang Y, Mosler EL, et al. Topical benzoyl peroxide for acne. *Cochrane Database Syst Rev*. 2020;(3). doi:10.1002/14651858.CD011154.pub2
18. Latter G, Grice JE, Mohammed Y, Roberts MS, Benson HAE. Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems. *Pharmaceutics*. 2019;11(10):490. doi:10.3390/pharmaceutics11100490
19. Imahiyerobo-Ip JI, Dinulos JG. Changing the topography of acne with topical medications. *Curr Opin Pediatr*. 2011;23(1):121-125. doi:10.1097/MOP.0b013e3283425457
20. Habeshian KA, Cohen BA. Current Issues in the Treatment of Acne Vulgaris. *Pediatrics*. 2020;145(Supplement_2):S225-S230. doi:10.1542/peds.2019-2056L
21. Sevimli Dikicier B. Topical treatment of acne vulgaris: efficiency, side effects, and adherence rate. *J Int Med Res*. 2019;47(7):2987-2992. doi:10.1177/0300060519847367
22. Arif T. Salicylic acid as a peeling agent: a comprehensive review. *Clin Cosmet Investig Dermatol*. 2015;8:455-461. doi:10.2147/CCID.S84765
23. Zhao J, Zhou B, Hou Y, Li L, Zhuo F. Effect of 5% glycolic acid complex and 20% glycolic acid on mild-to-moderate facial acne vulgaris. *Chin Med J (Engl)*. 2022;135(21):2614. doi:10.1097/CM9.0000000000002287
24. Tang SC, Yang JH. Dual Effects of Alpha-Hydroxy Acids on the Skin. *Molecules*. 2018;23(4):863. doi:10.3390/molecules23040863
25. Al-Talib H, Al-Khateeb A, Hameed A, Murugaiah C. Efficacy and safety of superficial chemical peeling in treatment of active acne vulgaris. *An Bras Dermatol*. 2017;92(2):212-216. doi:10.1590/abd1806-4841.20175273
26. Mavranzouli I, Daly CH, Welton NJ, et al. A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris*. *Br J Dermatol*. 2022;187(5):639-649. doi:10.1111/bjd.21739
27. Farrah G, Tan E. The use of oral antibiotics in treating acne vulgaris: a new approach. *Dermatol Ther*. 2016;29(5):377-384. doi:10.1111/dth.12370
28. Del Rosso JQ. Topical and oral antibiotics for acne vulgaris. *Semin Cutan Med Surg*. 2016;35(2):57-61. doi:10.12788/j.sder.2016.025
29. Paichitrojjana A, Paichitrojjana A. Oral Isotretinoin and Its Uses in Dermatology: A Review. *Drug Des Devel Ther*. 2023;17:2573-2591. doi:10.2147/DDDT.S427530
30. Turk CB, Baykara Uluşan M, Döş YM, Manav Baş V, Sarıkaya Tellal E, Koku Aksu AE. The Effects of Oral Isotretinoin on Atrophic Acne Scars Measured by Shear-wave Elastography: An Observational, Single-center Study. *J Clin Aesthetic Dermatol*. 2023;16(9):46-51.
31. Pile HD, Sadiq NM. Isotretinoin. In: *StatPearls*. StatPearls Publishing; 2024. Accessed August 13, 2024. <http://www.ncbi.nlm.nih.gov/books/NBK525949/>

32. Kapała J, Lewandowska J, Placek W, Owczarczyk-Saczonek A. Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis. *Int J Environ Res Public Health*. 2022;19(11):6463. doi:10.3390/ijerph19116463
33. Requena C, Llombart B. Oral Contraceptives in Dermatology. *Actas Dermosifiliogr*. 2020;111(5):351-356. doi:10.1016/j.ad.2019.06.006
34. Vargas-Mora P, Morgado-Carrasco D. Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. *Actas Dermosifiliogr*. 2020;111(8):639-649. doi:10.1016/j.ad.2020.03.001
35. Santer M, Lawrence M, Renz S, et al. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. *BMJ*. 2023;381:e074349. doi:10.1136/bmj-2022-074349
36. Han JJ, Faletsky A, Barbieri JS, Mostaghimi A. New Acne Therapies and Updates on Use of Spironolactone and Isotretinoin: A Narrative Review. *Dermatol Ther*. 2021;11(1):79-91. doi:10.1007/s13555-020-00481-w
37. Tai M, Zhang C, Ma Y, et al. Acne and its post-inflammatory hyperpigmentation treatment by applying anti-acne dissolving microneedle patches. *J Cosmet Dermatol*. 2022;21(12):6913-6919. doi:10.1111/jocd.15352
38. Moftah NH, Mansour AM, Ibrahim SMA. Clinical evaluation of efficacy of intralesional platelet-rich plasma injection versus 1064 nm long-pulsed Neodymium:YAG laser in the treatment of inflammatory acne vulgaris in adolescent and post-adolescent patients: a prospective randomized split-face comparative study. *Lasers Med Sci*. 2022;37(5):2471-2478. doi:10.1007/s10103-022-03510-6